亚太药业: 半年报董事会决议公告

Group 1 - The board of directors of Zhejiang Apac Pharmaceutical Co., Ltd. held its fourth meeting of the eighth session on August 28, 2025, with all nine directors participating in the voting [1][2] - The board unanimously approved the proposal regarding the provision for credit impairment losses and asset impairment losses, with 9 votes in favor and no votes against or abstaining [1] - The 2025 semi-annual report and its summary were also approved by the board with the same voting outcome, indicating strong consensus among the directors [2]